AU1596099A - Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists - Google Patents
Aryl and heteroaryl compounds useful as fibroblast growth factor antagonistsInfo
- Publication number
- AU1596099A AU1596099A AU15960/99A AU1596099A AU1596099A AU 1596099 A AU1596099 A AU 1596099A AU 15960/99 A AU15960/99 A AU 15960/99A AU 1596099 A AU1596099 A AU 1596099A AU 1596099 A AU1596099 A AU 1596099A
- Authority
- AU
- Australia
- Prior art keywords
- aryl
- growth factor
- fibroblast growth
- compounds useful
- heteroaryl compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/024875 WO2000030632A1 (en) | 1998-11-23 | 1998-11-23 | Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1596099A true AU1596099A (en) | 2000-06-13 |
Family
ID=22268348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU15960/99A Abandoned AU1596099A (en) | 1998-11-23 | 1998-11-23 | Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1596099A (en) |
WO (1) | WO2000030632A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003217276A1 (en) * | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Method of treating atherosclerosis and hypercholesterolemia |
CN1777425A (en) * | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | Muscarinic M1 receptor agonists for pain management |
JP4200222B2 (en) * | 2004-12-06 | 2008-12-24 | 国立大学法人九州大学 | Staining composition used for ophthalmic staining |
CN105412945B (en) | 2010-04-02 | 2021-02-05 | 药物影像股份有限公司 | Single isomeric conjugates of rhodamine dyes |
EP2849752B1 (en) * | 2012-10-26 | 2018-02-21 | Canon Kabushiki Kaisha | Cancer cell inhibitory drug and cancer stem-cell detection probe |
US9567291B2 (en) | 2013-04-25 | 2017-02-14 | Emory University | N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) |
CN116332808A (en) * | 2023-04-06 | 2023-06-27 | 长春百纯和成医药科技有限公司 | Tetrahalophenol tetrahalogen sulfophthalein alkali metal salt and preparation method thereof |
CN116375612A (en) * | 2023-04-06 | 2023-07-04 | 吉林医药学院 | 3,4,5,6-tetrahalophenol sulfophthalein alkali metal salt and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189056A (en) * | 1989-12-19 | 1993-02-23 | University Of North Carolina At Chapel Hill | Protection of moist stratified squamous epithelia against damage from noxious luminal agents |
US5434185A (en) * | 1993-05-17 | 1995-07-18 | The University Of Kentucky Research Foundation | Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts |
DE69528992T2 (en) * | 1994-09-16 | 2003-09-18 | Children's Medical Center Corp., Boston | USE OF AROMATIC HALOGEN COMPOUNDS FOR TREATING CELL POLLIFERATION IN MAMMALS |
EP0918514B9 (en) * | 1996-03-20 | 2006-07-05 | President And Fellows Of Harvard College | Triaryl methane compounds for the treatment of cancer, actinic keratosis and kaposi's sarcoma |
WO1998057922A1 (en) * | 1997-06-17 | 1998-12-23 | Sumitomo Chemical Company, Limited | Triphenylmethane derivatives and use thereof |
WO1999027921A2 (en) * | 1997-12-03 | 1999-06-10 | Eisai Co., Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
AU1903799A (en) * | 1997-12-05 | 1999-06-28 | Eisai Co. Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
-
1998
- 1998-11-23 AU AU15960/99A patent/AU1596099A/en not_active Abandoned
- 1998-11-23 WO PCT/US1998/024875 patent/WO2000030632A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2000030632A1 (en) | 2000-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2960599A (en) | Quinazoline derivatives | |
AU5759999A (en) | Pyrimidone derivatives | |
AU1252897A (en) | Substituted quinazoline derivatives | |
AU6274298A (en) | Growth differentiation factor-8 | |
AU7989400A (en) | Compounds and methods | |
AU3215500A (en) | Compounds and methods | |
AU3924300A (en) | Fibroblast growth factor-20 | |
AU4556700A (en) | Pyrimidine compounds | |
AU2586199A (en) | Growth differentiation factor-8 | |
AU6271498A (en) | Growth differentiation factor-11 | |
AU5391099A (en) | Substituted quinazoline derivatives | |
AU2220801A (en) | Tricyclic compounds and addition salts thereof | |
AU4395399A (en) | Five-membered heteroaryl compounds | |
AU1039199A (en) | Heparin-binding growth factor derivatives | |
AU4688499A (en) | Fibroblast growth factor receptor-5 | |
AU7419300A (en) | Quinazolinones | |
AU1596099A (en) | Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists | |
AU8586198A (en) | Growth differentiation factor, lefty-1 | |
AU8580098A (en) | Growth differentiation factor, lefty-2 | |
AU5914299A (en) | Antagonists of fibroblast growth factor | |
AU5706000A (en) | Useful polypeptide | |
AU5849300A (en) | Proliferation differentiation factor | |
AU7654800A (en) | Quinazolinones | |
AU5440800A (en) | Fibroblast growth factor 10 | |
AU5268000A (en) | Fibroblast growth factor 15 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |